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Objectives: The Cox maze procedure was developed as a surgical treatment for atrial fibrillation. However, atrial
fibrillation recurs in some patients, and atrial remodeling in the form of fibrosis can lead to perpetuation of atrial
fibrillation. To identify the predictor of the persistence of atrial fibrillation after the maze procedure using cryoa-
blation, we evaluated the preoperative plasma transforming growth factor b1. We also examined the correlations
between plasma transforming growth factor b1 levels and the degree of atrial fibrosis.
Methods: Preoperative plasma transforming growth factor b1 levels were measured in 86 consecutive patients
(age, 54  12 years) who underwent both the open heart operation for valvular heart disease and the surgical
maze procedure with cryoablation for persistent atrial fibrillation. We measured the degree of fibrosis from the
tissue of the left atrium.
Results: At 1 year’s follow-up, 10 of 86 patients had persistent atrial fibrillation. Patients with persistent atrial
fibrillation had higher preoperative plasma transforming growth factor b1 levels than the patients with sinus
rhythm (0.44  0.29 vs 0.32  0.15 ng/mL, P ¼ .03). Patients with persistent atrial fibrillation had higher
mRNA expressions of collagen III and lower mRNA expressions of atrial natriuretic peptide than those with sinus
rhythm, and the plasma transforming growth factor b1 levels correlated with the degree of fibrosis in the left
atrium (r ¼ 0.497, P ¼ .022). Multiple logistic regression analysis revealed that plasma transforming growth
factor b1 levels were independently associated with the postoperative persistence of atrial fibrillation at 1 year’s
follow-up.
Conclusions: Preoperative plasma transforming growth factor b1 levels could be used to predict the persistence
of atrial fibrillation at 1 year’s follow-up after the surgical maze procedure by using cryoablation. Preoperative
plasma transforming growth factor b1 levels were correlated with the degree of fibrosis in the left atria of patients
with mitral valvular heart disease.E
TThe Cox maze procedure was developed as a surgical treat-
ment of atrial fibrillation (AF), which aims to eliminate
anatomically determined re-entrant circuits by creating con-
tiguous lines of scar tissue between the pulmonary veins and
the mitral valve annulus.1 Restoration of sinus rhythm (SR)
has been reported to be successful in 75% to 95% of
patients undergoing the Cox maze procedure.2-4
Atrial remodeling leads to perpetuation of AF. Structural
remodeling in the form of fibrosis alters the substrate. There-
fore the success rate of the maze operation might be related
to the degree of atrial fibrosis. Among many echocardio-
graphic parameters and biomarkers, left atrial dimension in
echocardiographic analysis, AF duration,5,6 plasma atrial
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a few cytokines, such as transforming growth factor (TGF)
b1, collagen I, and collagen III, have been reported as pre-
dictors of the outcome of the maze procedure.8
To identify the predictors of the persistence of AF after the
maze procedure with cryoablation, we evaluated the role of
preoperative plasma TGF-b1 and evaluated the degree of
atrial fibrosis in histology in patients who underwent both
mitral valvular surgery and the maze procedure with cryoa-
blation because of persistent AF. We also examined the cor-
relations between plasma TGF-b1 levels and the degree of
atrial fibrosis in the left atrium.
MATERIALS AND METHODS
Patients
The trial was conducted between March 2005 and December 2006 in the
Departments of Cardiology and Thoracic and Cardiovascular Surgery, Car-
diovascular Center, Samsung Medical Center, Seoul, South Korea. Patients
requiring mitral valve surgery who also had a history of persistent AF were
eligible. The term longstanding persistent AF denotes the presence of unin-
terrupted AF for at least 6 months that showed no evidence of spontaneous
reversibility to SR. Patients with sick sinus syndrome, uncontrolled hyper-
thyroidism, a permanent pacemaker, or previous cardiac surgery were ex-
cluded. The protocol was approved by the institutional research ethics
committee. Written informed consent was obtained from all participants,rdiovascular Surgery c Volume 137, Number 6 1515
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TAbbreviations and Acronyms
AF ¼ atrial fibrillation
ANP ¼ atrial natriuretic peptide
ECG ¼ electrocardiogram
ELISA ¼ enzyme-linked immunosorbent assay
MMP ¼ matrix metalloproteinase
SR ¼ sinus rhythm
TGF ¼ transforming growth factor
and the recommendations of the revised version of the Declaration of Hel-
sinki were met.
Eighty-six consecutive patients (age, 54  12 years; 37 male and 49 fe-
male patients) who underwent both the open heart operation for mitral val-
vular heart disease and the surgical maze procedure for AF were enrolled.
The mean duration of AF before the surgical maze procedure was 3.4 years
(approximately 6 months to 15 years). The underlying mitral valvular heart
diseases were rheumatic heart disease in 58 patients and degenerative mitral
valvular disease in 28 patients.
The primary end point of the study was the persistence of AF during the
12-month follow-up period after the maze procedure with cryoablation.
Operations and the Maze Procedure
Operations were performed between March 2005 and December 2006.
All procedures were performed through a median sternotomy by using car-
diopulmonary bypass with bicaval venous drainage during moderate hypo-
thermia on an arrested heart. When performing a valve operation, the valve
was excised first, and then the maze procedure was performed, followed by
valve replacement or reconstruction. We simplified the procedure. Neither
atrial appendage was excised. Maze lesions were made by means of cryoa-
blation. Cryoablation lesions were created endocardially with a T-shaped
Cryoprobe (EP Technologies, Boston Scientific Corp, San Jose, Calif). Cry-
ogenerators were set at60C. Each cryoablation was delivered for 160 sec-
onds to achieve transmural lesions, as previously described.2
These lesions were made to isolate the pulmonary veins with the poste-
rior left atrial wall in conjunction with the left atriotomy incision by encir-
cling them all in one and also connecting the isolated area by creating lines
to the mitral annulus. A right-sided cryoablation lesion was applied at the
inferior vena cava to the coronary sinus from the tricuspid annulus to the in-
teratrial groove. If the right atrium was large or if the tricuspid valve incom-
petence was significant, another right-sided lesion was made from the right
atrial appendage to the tricuspid annulus. We did not place a lesion from the
superior vena cava to the inferior vena cava. Then the left atrial appendage
was over sewn from within the left atrium.
Blood and Tissue Sampling
Blood samples were obtained from peripheral veins at the day of the op-
eration. After centrifugation, the isolated plasma was stored before enzyme-
linked immunosorbent assay (ELISA). Tissue samples were randomly taken
just from the areas surrounding the left atriotomy from the left atrium at the
time of mitral valve surgery. A part of the tissue samples was processed for
pathology, and another part was immediately frozen in liquid nitrogen and
stored at80C.
Postoperative Follow-up
Cardiac rhythm was continuously monitored for 48 hours. Thereafter,
daily 12-lead electrocardiograms (ECGs) were obtained during hospitaliza-
tion. Per protocol, all patients stopped antiarrhythmic medication after the
maze operation with cryoablation. In patients who remained in AF after
the operation, electrical cardioversion was attempted. Warfarin was admin-1516 The Journal of Thoracic and Cardiovascular Suistered to all patients. Before hospital discharge, all patients underwent
transthoracic echocardiographic analysis. All patients were followed up at
1, 3, 6, 9, and 12 postoperative months. They had a clinical examination
and a 12-lead ECG. At 6 and 12 months, 24-hour Holter monitoring and
transthoracic echocardiographic analysis were also carried out. During fol-
low-up, if a patient reported symptoms suggestive of arrhythmia either at
a specified visit or between visits, 24-hour Holter monitoring was performed
(and an ECG was obtained, if appropriate), and if AF was observed, the pa-
tient was deemed to have reverted to AF at the next formal assessment. Like-
wise, the findings on any sporadic ECGs obtained by the patients’
physicians were similarly taken into account. At 1 year’s follow-up after
the maze procedure, 56 patients had maintained the restored SR, and 10 pa-
tients had persistent AF despite medical and electrocardioversion. Twenty
patients showed recurrent AF, which was converted to SR after application
of amiodarone.
Measurements of plasma cytokines levels. The levels of
plasma N-terminal prohormone brain-type natriuretic peptide, high-sensi-
tivity C-reactive protein, ANP, tissue inhibitor of metalloproteinase, TGF-
b1, matrix metalloproteinase (MMP) 3, and pro-MMP-1 were measured
by means of ELISAwith a Quantikine kit (R&D Systems, Inc, Minneapolis,
Minn). All samples were measured with the same batch of ELISA kits.
mRNA expressions of cytokines in left atrial tissue. Apart
of the resected left atrial tissues were frozen in liquid nitrogen and stored at
80C for Northern blot analysis to obtain molecular biologic evidence re-
garding the atrial qualitative differences between the AF and SR groups
(SR group, n ¼ 56; AF/SR group, n ¼ 20; AF group, n ¼ 10). Total
RNA was extracted with TRIzol reagent (Gibco BRL, Carlsbad, Calif) and
DNAwas transcripted with ThermoScript reverse transcriptase–polymerase
chain reaction systems (Gibco BRL). The expression of mRNA was semi-
quantified by using an internal standard of glyceraldehyde-3-phosphate
dehydrogenase.
Histology
Half of the resected left atrial samples were fixed in 6% buffered forma-
lin, embedded in paraffin, and stained with hematoxylin and eosin for rou-
tine histologic examination. Sections (5 mm) were stained with Masson
trichrome and Picro Sirius red for quantification of fibrosis. Sirius red–
stained slides were scanned, and the percentage of fibrosis was automati-
cally calculated with 5 random fields of each slide at the same magnification
(3400) in 22 randomly selected patients by using the Image Pro Plus pro-
gram (Media Cybernetics, Inc, Bethesda, Md).
Statistical Analysis
Summaryvalues are presentedasmeans standarddeviations.Categorical
variables were comparedwith thec2 test or Fisher’s exact test, and continuous
variables were compared with an unpaired t test or Mann–Whitney test as ap-
propriate. Correlation analysis was done with the Pearson correlation test.
Predictors of AF persistence were identified with univariate and multiple
logistic regression analysis. First, a series of variables were screened with uni-
variate analysis. Then the variables that attained aP value of less than .10were
entered into a multiple logistic regression model. Statistical analysis was per-
formed with SAS version 9.1 software (SAS Institute, Inc, Cary, NC).
RESULTS
At 1 year’s follow-up after the maze procedure, 56 of 86
consecutive patients had maintained the restored SR (SR
group, n ¼ 56), and 10 patients had persistent AF despite
medical and electrocardioversion (AF group, n ¼ 10).
Twenty patients showed recurrent AF, which was con-
verted to SR after medication (AF/SR group, n ¼ 20).
The clinical characteristics of patients are summarized inrgery c June 2009
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SR AF/SR AF P value
No. 56 20 10
Age (y) 52.5  10.2 57.8  14.3 57.5  13.0 .143
Sex (M/F) 26/30 8/12 3/7 .597
Hypertension 11 (20%) 6 (30%) 3 (30%) .556
DM 7 (12%) 4 (20%) 0 .301
Stroke/TIA 6 (11%) 2 (10%) 0 .557
Smoking 13 (23%) 5 (25%) 3 (30%) .556
Rheum/Degen 38/18 13/7 7/3 .957
AF duration (y) 3.2  4.2 3.3  3.1 4.8  5.2 .499
At 1 year’s follow-up after the maze procedure, 56 of 86 consecutive patients had maintained restored sinus rhythm (SR group, n ¼ 56), and 10 patients had persistent atrial
fibrillation despite medical and electrocardioversion (AF group, n¼ 10). Twenty patients showed recurrent atrial fibrillation, which was converted to sinus rhythm after medication
(AF/SR group, n ¼ 20). P values were determined by means of analysis of variance. SR, Sinus rhythm group; AF/SR, atrial fibrillation to sinus rhythm group; AF, atrial
fibrillation group; M, Male; F, female; DM, diabetes mellitus; TIA, transient ischemic attack; Rheum, rheumatic heart disease; Degen, degenerative heart disease.Table 1. Theprevalence of arterial hypertension, diabetesmel-
litus, stroke, or transient ischemic attack was not significantly
different among groups. The duration of AF looked similar
(P ¼ .499). The type of underlying valvular heart disease,
such as rheumatic or degenerative disease, was not different
among groups.
Among the echocardiographic parameters, the preopera-
tive left atrial volume index was larger in the AF group
than in the SR group (88.6  27.6 vs 118.5  51.6 mm3,
P < .05). Immediate postoperative left atrial diameters
were larger in the AF group than in the SR group (50.0 
6.1 vs 53.7  8.7 mm, P<.05, Table 2).
The AF group had higher plasma TGF-b1 levels than the
SR group (0.44  0.29 vs 0.32  0.15 ng/mL, P< .05,
Table 3).
The mRNA expressions of collagen IIIa (0.21  0.20 vs
0.12 0.12, P¼ .061 compared with internal standard glyc-
eraldehyde-3-phosphate dehydrogenase by means of reverse
transcriptase–polymerase chain reaction) were higher in AF
group, and the mRNA expressions of ANP were lower (0.31
 0.16 vs 0.60 0.76, P¼ .013) in the AF group than in the
SR group (Tables 4 and 5).Multiple logistic regression analysis revealed that plasma
TGF-b1 levels were independently associated with the post-
operative persistence of AF at 1 year’s follow-up after the
surgical maze procedure (Table 6).
In Masson trichrome and Sirius red staining, more fibrosis
was identified in the AF group. The degree of fibrosis was
correlated with the echocardiographic left atrial diameter,
left atrial volume index, and preoperative plasma TGF-b1
level (Figures 1 and 2).
Plasma TGF-b1 levels of greater than 0.30 ng/mL had
a sensitivity of 70.0% and a specificity of 60.8% for the
postoperative persistence of AF at 1 year’s follow-up after
the surgical maze procedure with cryoablation.
DISCUSSION
The importance of fibrosis appears to be increased in
patients with persistent AF. Atrial fibrosis provides a
pathophysiologic substrate for postoperative AF (ie,
arrhythmogenic substrate for AF).9,10
Patients with chronic AF were shown to have higher
levels of myocardial interstitial fibrosis compared with con-
trol subjects, who are known to be arrhythmogenic.11-13E
TTABLE 2. Echocardiographic parameters of the patients
SR AF/SR AF P value
No. 56 20 10
Preoperative echocardiographic
analysis
LAD (mm) 59.1  7.1 63.1  7.9 63.2  7.5 .060
LAVI (mm3) 88.6  27.6 102.4  30.8 118.5  51.6* .021
Postoperative echocardiographic
analysis (before discharge)
LAD (mm) 50.0  6.1 52.9  5.7 53.7  8.7* .044
LAVI (mm3) 57.9  15.1 63.5  15.7 68.1  19.2 .127
Preoperative left atrial volume index and postoperative left atrial diameter were larger in the persistent AF group. P values were determined by means of analysis of variance. SR,
Sinus rhythm group; AF/SR, atrial fibrillation to sinus rhythm group; AF, atrial fibrillation group; LAD, Left atrial diameter; LAVI, Left atrial volume index. *P< .05 compared
with the SR group.
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TTABLE 3. Biochemical markers among groups
SR AF/SR AF P value
No. 56 20 10
NT-proBNP (pg/mL) 1849  3959 1991  2347 1154  905 .807
hsCRP (mg/dL) 0.37  1.50 0.50  1.34 0.20  0.21 .857
ANP (ng/mL) 6.32  6.19 5.16  2.91 3.97  1.65 .367
TIMP-1 (ng/mL) 1.32  0.72 1.38  0.75 1.35  0.81 .951
TGF-b1 (ng/mL) 0.32  0.15 0.27  0.11 0.44  0.29* .030
MMP-3 (ng/mL) 1.10  0.94 0.87  0.45 0.78  0.45 .359
Pro-MMP-1 (ng/mL) 1.58  1.26 1.50  1.66 1.34  0.81 .861
Preoperative cytokines were measured by means of enzyme-linked immunosorbent assay. Plasma transforming growth factor b1 levels were increased in the AF group. P values
were determined by means of analysis of variance. SR, Sinus rhythm group; AF/SR, atrial fibrillation to sinus rhythm group; AF, atrial fibrillation group; NT-proBNP, N-terminal
prohormone brain natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; ANP, atrial natriuretic protein; TIMP, tissue inhibitor of metalloproteinase; MMP, matrix metal-
loproteinase; TGF-b1, Transforming growth factor b1. *P< .05 compared with the SR group.The precise mechanisms and signaling pathways involved
in the development of atrial fibrosis are unknown. It appears
that the atrium is more susceptible to atrial fibrosis than is the
ventricle, and currently, 3 interrelated pathways appear to be
involved: the renin–angiotensin system, TGF-b1, and the
oxidative stress pathways.12
Fibrosis is thought to be partially mediated by TGF-b1,
a potent stimulator of collagen-producing cardiac fibro-
blasts. TGF-b1 is a profibrotic cytokine that stimulates the
production of extracellular matrix proteins in organs. Fur-
thermore, in animals overexpression of TGF-b results in tis-
sue fibrosis and organ dysfunction. The pathogenic effects of
TGF-b1 have now been suggested to play a major role in
valvular disease and arrhythmia, particularly AF. In a trans-
genic mouse model13 constitutional activation of TGF-b1
produces atrial restricted fibrosis and promotes AF in-
ducibility. TGF-b1–associated fibrosis results in an inho-
mogeneous substrate for electrical propagation. This
environment impedes anisotropic or linear conduction
leading to the development of arrhythmia.13-15 TGF-b1
has been shown to increase connective tissue growth fac-
tor synthesis within different fibroblast subtypes, includ-
ing cardiac fibroblasts, most probably by acting on
TGF-b1 response elements localized in the connective
tissue growth factor promoter site.16Homeostasis of the extracellular matrix is a balance
between synthesis and degradation. Proteolytic enzymes,
such as MMPs, play an important role in promoting change
and remodeling.15,17 By breaking down the extracellular ma-
trix, MMPs contribute to matrix turnover, to dilatation, and
to structural remodeling. The roles of TGF-b1 and MMPs in
cardiac remodeling might be intertwined, which allows for
the local production of extracellular proteins and increased
fibrosis within the myocardium of the heart associated
with cardiac remodeling.
Myocardial fibrosis plays an important role in predisposi-
tion to arrhythmia.11 Mice with increased expression of
TGF-b1 were prone to AF as a result of increased levels
of atrial fibrosis.13 TGF-b1 plays an important role within
the ‘‘AF begets AF’’ remodeling process.
Patients with AF display increased atrial fibrous tissue
content, along with increased expression of collagen I and
III.18 The composition of the extracellular matrix might pro-
vide a substrate for the initiation of postoperative AF.19,20
The plasma ANP level might reflect atrial degenerative
change and might predict the outcome of the maze proce-
dure. Yoshihara and colleagues7 reported that the preopera-
tive plasma ANP level was significantly lower in the AF
group than in the SR group. The mRNA expression of
ANP in the left atrial appendage tissues was alsoTABLE 4. mRNA expressions of cytokines in left atrial tissue among groups
SR AF/SR AF P value
No. 56 20 10
ANP 0.60  0.76 0.48  0.49 0.31  0.16* .396
BNP 0.14  0.24 0.09  0.13 0.17  0.18 .520
TGF-b1 0.19  0.23 0.19  0.17 0.22  0.18 .905
CTGF 0.23  0.23 0.28  0.25 0.19  0.21 .600
Collagen Ia 0.12  0.15 0.12  0.11 0.17  0.21 .666
Collagen IIIa 0.12  0.12 0.14  0.15 0.21  0.20 .183
The internal standard was glyceraldehyde-3-phosphate dehydrogenase. mRNA expressions were not different among groups. P values were determined by means of analysis of
variance. SR, Sinus rhythm group; AF/SR, atrial fibrillation to sinus rhythm group; AF, atrial fibrillation group; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide;
TGF-b1, transforming growth factor b1; CTGF, connective tissue growth factor. *P< .05 compared with the SR group.
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markers to predict the persistence of atrial fibrillation at 1 year’s
follow-up in the AF and SR groups
SR AF P value
No. 56 10
Age (y) 52.5  10.2 57.5  13.0 .173
AF duration (y) 3.2  4.2 4.8  5.2 .270
Preoperative
echocardiography
LAD (mm) 59.1  7.1 63.2  7.5 .101
LAVI (mm3) 88.6  27.6 118.5  51.6 .012
Postoperative
echocardiography
LAD (mm) 50.0  6.1 53.7  8.7 .068
LAVI (mm3) 57.9  15.1 68.1  19.2 .077
Biologic markers
NT-proBNP (pg/mL) 1849  3959 1154  905 .585
hsCRP (mg/dL) 0.37  1.50 0.20  0.21 .724
ANP (ng/mL) 6.32  6.19 3.97  1.65 .240
TIMP-1 (ng/mL) 1.32  0.72 1.35  0.81 .901
TGF-b1 (ng/mL) 0.32  0.15 0.44  0.29 .055
MMP-3 (ng/mL) 1.10  0.94 0.78  0.45 .301
Pro-MMP-1 (ng/mL) 1.58  1.26 1.34  0.81 .559
mRNA expression
ANP 0.60  0.76 0.31  0.16 .013
BNP 0.14  0.24 0.17  0.18 .633
TGF-b1 0.19  0.23 0.22  0.18 .678
CTGF 0.23  0.23 0.19  0.21 .556
Collagen Ia 0.12  0.15 0.17  0.21 .444
Collagen IIIa 0.12  0.12 0.21  0.20 .061
SR, Sinus rhythm group; AF, atrial fibrillation group; LAD, left atrial diameter;
LAVI, left atrial volume index; NT-proBNP, N-terminal prohormone brain natri-
uretic peptide; hsCRP, high-sensitivity C-reactive protein; ANP, atrial natriuretic
peptide; TIMP-1, tissue inhibitor of metalloproteinase 1; TGF-b1, transforming
growth factor b1; MMP, matrix metalloproteinase; CTGF, connective tissue
growth factor.significantly lower in the AF group than in the SR group, and
the collagen volume fraction correlated negatively with
plasma ANP levels. In this study we found that the patients
with AF persistence had higher messenger RNA expressions
of collagen IIIa and lower mRNA expressions of ANP than
the patients with SR.
Previous studies21,22 have demonstrated that in patients
with mitral valve disease who are undergoing the surgical
maze procedure for AF, the sinus conversion rates decrease
as the preoperative left atrial dimensions increase, and the
preoperative left atrial area was a determinant of sinus con-
version by using the radiofrequency maze procedure for pa-
tients with permanent AF and mitral valve disease. We have
similar results, and the left atrial dimension and the left atrial
volume index are associated with the persistence of AF at 1
year after the maze procedure.
TABLE 6. Biomarkers to predict persistent atrial fibrillation 1 year
after the maze operation
B P value
Preoperative echocardiography
LAD (mm) 0.406 .108
LAVI (mm3) 0.078 .071
Postoperative echocardiography
LAD (mm) 0.339 .135
LAVI (mm3) 0.016 .760
TGF-b1 (ng/mL) 10.934 .042
ANP 4.857 .108
Collagen Ia 8.616 .229
Collagen IIIa 12.890 .126
Preoperative plasma levels of transforming growth factor b1 could predict the persis-
tency of atrial fibrillation in multiple logistic regression analysis. LAD, Left atrial
diameter; LAVI, left atrial valve diameter; TGF-b1, transforming growth factor b1;
ANP, atrial natriuretic peptide.E
TFIGURE 1. Comparisons of the areas of fibrosis in the left atrium among groups. Collagen is stained in blue in Masson trichrome staining (A-C) and red in
Sirius red staining (D-F) in the left atrium of the sinus rhythm group (A and D), the atrial fibrillation to sinus rhythm group (B and E), and the atrial fibrillation
group (C and F). (Original magnification 3100.)
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TC-reactive protein is an acute-phase protein and is an ex-
quisitely sensitive systemic marker of inflammation. C-reac-
tive protein is not only associated with the presence of AF
but might also predict patients at increased risk for future
development of AF.23
We have some limitations, and small sample size might
account for why some of the characteristics were of border-
line significance in the multivariable analysis, in particular
characteristics that other authors have found to be significant
predictors in recurrent AF.
CONCLUSIONS
Preoperative plasma TGF-b1 levels could predict the per-
sistence of AF at 1 year’s follow-up in patients who under-
went both mitral valvular surgery and the maze procedure
with cryoablation because of persistent AF, and preoperative
plasma TGF-b1 levels were correlated with the degree of
fibrosis in the left atria of patients with mitral valvular heart
disease.
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